An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT03001882 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

230

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Nivolumab
BIOLOGICAL: Ipilimumab

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]